![Alberto Bianchinotti](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alberto Bianchinotti
Directeur Financier/CFO chez
LF CAPITAL ACQUISITION CORP. II
Profil
Alberto Bianchinotti is currently the Chief Financial Officer at Merlin Nexus and LF Capital Acquisition Corp.
II.
In the past, he worked as an Analyst at Merlin Biomed Group Hedge Funds and as a Supervisor at Anchin, Block & Anchin LLP.
He also served as the Chief Financial Officer at LF Capital Acquisition Corp.
Mr. Bianchinotti received his undergraduate degree from the State University of New York at Binghamton in 1999.
Postes actifs de Alberto Bianchinotti
| Sociétés | Poste | Début |
|---|---|---|
| LF CAPITAL ACQUISITION CORP. II | Directeur Financier/CFO | 01/03/2021 |
Merlin Nexus
 Merlin Nexus Investment ManagersFinance Merlin Nexus invests in both private and public life sciences companies across the globe. The firm focuses on sectors such as biotechnology, medical devices, molecular diagnostics, and specialty pharmaceuticals. It participates in late-stage and PIPE (Private Investments in Public Equity) transactions. | Directeur Financier/CFO | 01/01/2007 |
Anciens postes connus de Alberto Bianchinotti
| Sociétés | Poste | Fin |
|---|---|---|
Merlin Biomed Group Hedge Funds
 Merlin Biomed Group Hedge Funds Investment ManagersFinance Merlin BioMed invests globally in public and private healthcare companies. The firm's hedge funds and long-term appreciation fund seek maximum capital appreciation from broad-based, global investment in small-, mid- and large-cap public and private companies in the areas of biotechnology, pharmaceuticals, medical devices, healthcare services and research products/services. This investment objective is characterized by an intensive, research-oriented, fundamental, bottom-up approach with a focus on new product innovation as a driver of sales and earnings growth. For private equity, the MerlinNexus objective is to realize long-term capital appreciation from investments in late-stage private companies, PIPEs (private investments in public entities) and select open market transactions. The fund is invested in all segments of the healthcare industry, with an emphasis on product-driven life sciences companies developing breakthrough products that meet clinical needs and can positively alter disease course and associated costs. | Analyst-Equity | 31/12/2006 |
Anchin, Block & Anchin LLP
 Anchin, Block & Anchin LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, tax and advisory services | Corporate Officer/Principal | 30/06/2004 |
| LF CAPITAL ACQUISITION CORP. | Directeur Financier/CFO | - |
Formation de Alberto Bianchinotti
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
90
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Merlin Biomed Group Hedge Funds
Merlin Biomed Group Hedge Funds Investment ManagersFinance Merlin BioMed invests globally in public and private healthcare companies. The firm's hedge funds and long-term appreciation fund seek maximum capital appreciation from broad-based, global investment in small-, mid- and large-cap public and private companies in the areas of biotechnology, pharmaceuticals, medical devices, healthcare services and research products/services. This investment objective is characterized by an intensive, research-oriented, fundamental, bottom-up approach with a focus on new product innovation as a driver of sales and earnings growth. For private equity, the MerlinNexus objective is to realize long-term capital appreciation from investments in late-stage private companies, PIPEs (private investments in public entities) and select open market transactions. The fund is invested in all segments of the healthcare industry, with an emphasis on product-driven life sciences companies developing breakthrough products that meet clinical needs and can positively alter disease course and associated costs. | Finance |
Anchin, Block & Anchin LLP
Anchin, Block & Anchin LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, tax and advisory services | Commercial Services |
Merlin Nexus
Merlin Nexus Investment ManagersFinance Merlin Nexus invests in both private and public life sciences companies across the globe. The firm focuses on sectors such as biotechnology, medical devices, molecular diagnostics, and specialty pharmaceuticals. It participates in late-stage and PIPE (Private Investments in Public Equity) transactions. | Finance |
State University of New York at Binghamton
 State University of New York at Binghamton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LF Capital Acquisition Corp.
 LF Capital Acquisition Corp. Financial ConglomeratesFinance Provides investment services | Finance |
LF Capital Acquisition Corp. II
 LF Capital Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
